Michael Ehlers
General Partner at ATP
Michael Ehlers
General Partner at ATP
Cambridge, Massachusetts
Overview
Work Experience
Chief Scientific Officer, General Partner
2024 - Current
Chief Scientific Officer, Venture Partner
2019 - 2024
Apple Tree Partner's (ATP’s) unique model follows the science, brings together the best teams, and deploys significant capital to create and build the next generation of innovative biotechnology companies.
Founder, President, and Chief Executive Officer
2023
Lead all activities at a research stage biotechnology company focused on designer synthetic RNA therapeutics and RNA exon editing. Deploying innovative technology platforms to create breakthrough therapies for debilitating ophthalmological, neurological, neuromuscular, and rare diseases.
Founder and Board Chair
2022 - 2023
Scientific and corporate leadership of research stage biotechnology company developing designer synthetic RNA therapeutics and RNA exon editing therapies for ophthalmological, neurological, neuromuscular, and rare diseases.
Founder, President and Chief Executive Officer
2020 - 2022
Lead all activities at a research stage biotechnology company focused on designer synthetic RNA therapeutics and RNA exon editing. Deploying innovative technology platforms to create breakthrough therapies for debilitating ophthalmological, neurological, neuromuscular, and rare diseases.
Co-Founder and Board Chair
2021
Scientific and corporate leadership of research stage biotechnology company developing novel self-replicating RNA therapies for cancer, autoimmune disorders, and infectious diseases.
Co-Founder and Board Chair
2020
Scientific and corporate leadership of research stage biotechnology company developing novel immunotherapies for the treatment of diverse cancers.
Founder and Board Chair
2023 - 2023
Scientific and corporate leadership of research stage biotechnology company developing non-viral gene therapies for ophthalmological diseases.
Founder, President, and Chief Executive Officer
2020 - 2023
Led all activities at a cutting-edge start-up biotechnology company focused on non-viral gene therapy. Deploying molecular biology and bioengineering platforms to create breakthrough therapies in ophthalmology.
Chief Executive Officer
2019 - 2020
Led a cutting-edge start-up biotech company focused on gene therapy and genetic medicines for patients with severe inherited diseases.
Executive Vice President
2016 - 2019
led global R&D for a cutting edge, industry-leading biotechnology company
Group Senior Vice President, BioTherapeutics
2015 - 2016
Lead R&D activites in a large division of a leading biopharmaceutical company.
Senior Vice President, Chief Scientific Officer for Neuroscience
2010 - 2016
lead global research and development in neuroscience to create innovative medicines that effectively treat brain disorders
SVP, CSO Neuroscience
2010 - 2011
SVP, CSO Neuroscience
2010 - 2011
Investigator
2005 - 2010
Professor of Neurobiology
1998 - 2010